BioWorld

Oct. 6, 2008

View Archived Issues

Deciphera's B-Raf Inhibitor Program Lands Deal with Lilly

Privately held Deciphera Pharmaceuticals LLC signed its first big pharma deal, licensing rights to four preclinical B-Raf kinase inhibitors to Eli Lilly and Co. for the development of oncology drugs. (BioWorld Today) Read More

Another Case of PML: This Time Raptiva is Implicated

Read More

Repros Looks Inside to Close $15.5M Registered Direct Deal

Read More

NCI Studying Biomarker Use in Lung Cancer Treatment

Read More

Judge Says Amgen Entitled to Permanent Injunction in EPO Case

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More